{
    "id": 32832,
    "fullName": "FBXW7 W606*",
    "impact": "nonsense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "FBXW7 W606* results in a premature truncation of the Fbxw7 protein at amino acid 606 of 707 (UniProt.org). W606* has been identified in the scientific literature (PMID: 27870570), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Mar 2020).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 8167,
                    "pubMedId": 27870570,
                    "title": "Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27870570"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 55294,
        "geneSymbol": "FBXW7",
        "terms": [
            "FBXW7",
            "AGO",
            "CDC4",
            "FBW6",
            "FBW7",
            "FBX30",
            "FBXO30",
            "FBXW6",
            "hAgo",
            "hCdc4",
            "SEL-10",
            "SEL10"
        ]
    },
    "variant": "W606*",
    "createDate": "03/19/2020",
    "updateDate": "03/19/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 21021,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Sutent (sunitinib) treatment resulted in rapid disease progression in a patient with metastatic adenoid cystic carcinoma harboring co-occurring NOTCH1 L1600Q and S2467fs, and acquired FBXW7 W606* and NOTCH1 V1721G (PMID: 27870570).",
            "molecularProfile": {
                "id": 35498,
                "profileName": "FBXW7 W606* NOTCH1 L1600Q NOTCH1 V1721G NOTCH1 S2467fs"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 80202,
                "name": "adenoid cystic carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8167,
                    "pubMedId": 27870570,
                    "title": "Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27870570"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21020,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, FBXW7 W606* and NOTCH1 V1721G were identified at disease progression in a patient with metastatic adenoid cystic carcinoma harboring co-occurring NOTCH1 L1600Q and S2467fs who was treated with Brontictuzumab (OMP-52M51) (PMID: 27870570).",
            "molecularProfile": {
                "id": 35498,
                "profileName": "FBXW7 W606* NOTCH1 L1600Q NOTCH1 V1721G NOTCH1 S2467fs"
            },
            "therapy": {
                "id": 839,
                "therapyName": "Brontictuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 80202,
                "name": "adenoid cystic carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 8167,
                    "pubMedId": 27870570,
                    "title": "Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27870570"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35497,
            "profileName": "FBXW7 W606*",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35498,
            "profileName": "FBXW7 W606* NOTCH1 L1600Q NOTCH1 V1721G NOTCH1 S2467fs",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}